6.83
price up icon1.49%   0.10
after-market Dopo l'orario di chiusura: 6.83
loading
Precedente Chiudi:
$6.73
Aprire:
$6.64
Volume 24 ore:
1.01M
Relative Volume:
1.29
Capitalizzazione di mercato:
$368.68M
Reddito:
$2.81M
Utile/perdita netta:
$-97.34M
Rapporto P/E:
-4.3228
EPS:
-1.58
Flusso di cassa netto:
$-91.47M
1 W Prestazione:
-12.55%
1M Prestazione:
-0.15%
6M Prestazione:
+72.47%
1 anno Prestazione:
-24.20%
Intervallo 1D:
Value
$6.56
$7.12
Intervallo di 1 settimana:
Value
$6.50
$8.50
Portata 52W:
Value
$2.315
$10.13

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
Nome
Fulcrum Therapeutics Inc
Name
Telefono
617-651-8851
Name
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Dipendente
45
Name
Cinguettio
@fulcrumtx
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
FULC's Discussions on Twitter

Confronta FULC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FULC
Fulcrum Therapeutics Inc
6.83 363.28M 2.81M -97.34M -91.47M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-29 Aggiornamento H.C. Wainwright Neutral → Buy
2025-05-23 Aggiornamento Leerink Partners Market Perform → Outperform
2025-05-15 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2024-09-13 Downgrade H.C. Wainwright Buy → Neutral
2024-09-12 Downgrade BofA Securities Neutral → Underperform
2024-09-12 Downgrade Cantor Fitzgerald Overweight → Neutral
2024-09-12 Downgrade Leerink Partners Outperform → Market Perform
2024-09-12 Downgrade RBC Capital Mkts Outperform → Sector Perform
2024-09-12 Downgrade Stifel Buy → Hold
2024-09-09 Aggiornamento BofA Securities Underperform → Neutral
2024-05-20 Iniziato Cantor Fitzgerald Overweight
2024-03-13 Iniziato RBC Capital Mkts Outperform
2023-09-25 Iniziato Goldman Neutral
2023-08-23 Aggiornamento H.C. Wainwright Neutral → Buy
2023-08-22 Aggiornamento Stifel Hold → Buy
2023-05-04 Downgrade Goldman Buy → Neutral
2023-03-10 Downgrade Credit Suisse Outperform → Neutral
2023-03-10 Downgrade H.C. Wainwright Buy → Neutral
2023-03-09 Downgrade Stifel Buy → Hold
2023-02-28 Downgrade Morgan Stanley Overweight → Equal-Weight
2023-02-24 Downgrade BofA Securities Neutral → Underperform
2022-11-15 Iniziato Goldman Buy
2022-03-08 Iniziato Oppenheimer Outperform
2022-03-03 Aggiornamento BofA Securities Underperform → Neutral
2021-08-11 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-04-26 Ripresa Credit Suisse Outperform
2021-03-22 Iniziato Credit Suisse Outperform
2021-03-02 Iniziato Stifel Buy
2020-10-16 Iniziato Piper Sandler Overweight
2020-08-12 Downgrade BofA Securities Neutral → Underperform
2020-08-12 Reiterato H.C. Wainwright Buy
2020-08-12 Downgrade Morgan Stanley Overweight → Equal-Weight
2020-06-19 Downgrade BofA/Merrill Buy → Neutral
2020-06-17 Iniziato BTIG Research Buy
2019-10-03 Iniziato H.C. Wainwright Buy
2019-08-12 Iniziato BofA/Merrill Buy
Mostra tutto

Fulcrum Therapeutics Inc Borsa (FULC) Ultime notizie

pulisher
06:32 AM

Fulcrum Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with smart trades - jammulinksnews.com

06:32 AM
pulisher
05:37 AM

What catalysts could drive Fulcrum Therapeutics Inc. stock higher in 2025Build wealth with long-term growth strategies - jammulinksnews.com

05:37 AM
pulisher
05:15 AM

What are analysts’ price targets for Fulcrum Therapeutics Inc. in the next 12 monthsBuild a portfolio that stands the test of time - jammulinksnews.com

05:15 AM
pulisher
04:09 AM

Why is Fulcrum Therapeutics Inc. stock attracting strong analyst attentionMassive stock growth - jammulinksnews.com

04:09 AM
pulisher
02:11 AM

Is Fulcrum Therapeutics Inc. a good long term investmentUnlock powerful trading strategies for gains - jammulinksnews.com

02:11 AM
pulisher
01:23 AM

What analysts say about Fulcrum Therapeutics Inc. stockAchieve impressive returns with smart timing - jammulinksnews.com

01:23 AM
pulisher
01:07 AM

What is Fulcrum Therapeutics Inc. company’s growth strategyUnlock powerful market insights for success - jammulinksnews.com

01:07 AM
pulisher
12:24 PM

Fulcrum Therapeutics shares slide 17% after sickle cell trial results - MSN

12:24 PM
pulisher
10:04 AM

Technical signs of recovery in Fulcrum Therapeutics Inc.Price Spike Prediction for Active Traders - Newser

10:04 AM
pulisher
05:17 AM

Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Entry Optimization Guide with Volume Analysis - Newser

05:17 AM
pulisher
Aug 02, 2025

When is Fulcrum Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

How strong is Fulcrum Therapeutics Inc. company’s balance sheetMaximize returns with timely market signals - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

How does Fulcrum Therapeutics Inc. generate profit in a changing economyHigh-profit capital plays - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

What institutional investors are buying Fulcrum Therapeutics Inc. stockInvest smarter with cutting-edge analytics - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

Is Fulcrum Therapeutics Inc. stock overvalued or undervaluedAccess exclusive market insights for free - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

FY2025 EPS Estimates for FULC Raised by Cantor Fitzgerald - Defense World

Aug 02, 2025
pulisher
Aug 02, 2025

Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningTrend Confirmation Scanner with Entry Focus - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

Will Fulcrum Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsOversold Opportunity Scanner with RSI Data - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

Q3 Earnings Forecast for FULC Issued By Leerink Partnrs - Defense World

Aug 02, 2025
pulisher
Aug 02, 2025

Is Fulcrum Therapeutics Inc. stock ready for a breakoutReal-Time AI Entry Forecast Generator - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

Is Fulcrum Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Portfolio Diversification Stock Ideas - Newser

Aug 02, 2025
pulisher
Aug 01, 2025

Are Bears Losing Grip on Fulcrum Therapeutics Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it

Aug 01, 2025
pulisher
Aug 01, 2025

How to interpret RSI for Fulcrum Therapeutics Inc. stockTen-Year Sector Performance and Summary Analysis - Newser

Aug 01, 2025
pulisher
Jul 31, 2025

What is the risk reward ratio of investing in Fulcrum Therapeutics Inc. stockPre Market Insights For Beginners - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

How many analysts rate Fulcrum Therapeutics Inc. as a “Buy”Wealth Building Picks That Work - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.29 Consensus Target Price from Brokerages - Defense World

Jul 31, 2025
pulisher
Jul 31, 2025

Key External Factors That Drive Fulcrum Therapeutics Inc. Stock Price MovementsAI Trading Suggestions With Accuracy Focus Released - metal.it

Jul 31, 2025
pulisher
Jul 30, 2025

Fulcrum Therapeutics stock price target raised to $5 at RBC Capital - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Buy at HC Wainwright - Defense World

Jul 30, 2025
pulisher
Jul 30, 2025

Is Fulcrum Therapeutics Inc. building a consolidation baseTrend Following Ideas with Volume Confirmation - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Published on: 2025-07-30 02:00:45 - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Fulcrum Therapeutics 2024 Q2 Earnings Strong Turnaround with Net Income Swing of 333% - AInvest

Jul 30, 2025
pulisher
Jul 29, 2025

H.C. Wainwright upgrades Fulcrum Therapeutics stock rating on promising SCD data - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

HC Wainwright Raises Fulcrum Therapeutics' PT to $12 from $4 - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Inc. Stock Fails to Break Resistance Traders ReactDaily Smart Money Movement Monitor Activated - beatles.ru

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Plunges 29.58% on PIONEER Trial Results - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 1c - StreetInsider

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics stock falls after sickle cell disease trial results - Investing.com Australia

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics Reports Positive Results from Phase 1b PIONEER Trial of Pociredir for Sickle Cell Disease - Quiver Quantitative

Jul 29, 2025
pulisher
Jul 29, 2025

Fulcrum Therapeutics reports Q2 results, pociredir trial data - StreetInsider

Jul 29, 2025

Fulcrum Therapeutics Inc Azioni (FULC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Capitalizzazione:     |  Volume (24 ore):